CAP and BCAP have published technical amendments to CAP Section 12 and BCAP Section 11 to reflect changes to the regulatory frameworks for medicines and medical devices as a result of the UK’s exit from the EU. 

These changes include updating references to legislation underpinning the CAP and BCAP Code rules on advertising for medicines and medical devices, as well as other minor administrative changes. 

CAP and BCAP will continue to monitor ongoing developments in this area, such as proposals to extend acceptance of CE marking for medical devices in Great Britain, and consider making further technical changes to CAP Code Section 12 and BCAP Section 11 where necessary.